Monopar Therapeutics DEF 14A proxy statements
Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.
NASDAQ
Monopar Therapeutics Inc. has filed a definitive proxy statement (DEFA14A) with the U.S. Securities and Exchange Commission.
NASDAQ
Monopar Therapeutics will hold its annual stockholders meeting on June 17, 2025, to vote on director elections, executive compensation, and auditor ratification.
NASDAQ
DEF 14A: Monopar Therapeutics Seeks Stockholder Approval for Reverse Stock Split and Incentive Plan Amendment
Monopar Therapeutics is asking stockholders to approve a reverse stock split and an amendment to their stock incentive plan at the upcoming annual meeting on August 5, 2024.